Real-world implementation and cost impact analysis of Oncotype DX testing in early-stage breast cancer

Niina Mäenpää, Leena Tiainen, Janne Martikainen, Minna Tanner, Arja Jukkola, Maarit Bärlund · 2026

Read Real-world implementation and cost impact analysis of Oncotype DX testing in early-stage breast cancer by Niina Mäenpää, Leena Tiainen, Janne Martikainen, Minna Tanner, Arja Jukkola, Maarit Bärlund (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0353941.txt.

Description

Niina Mäenpää and five colleagues report what happened when a Finnish hospital adopted a gene test that predicts whether early breast cancer needs chemotherapy, in this 2026 PLOS ONE study. One hundred and twenty-nine patients with hormone-sensitive, HER2-negative tumours were tested over two years. The assay reads the tumour's gene activity and estimates both recurrence risk and likely chemotherapy benefit.

Testing changed recommendations for most patients: nearly three quarters were spared chemotherapy they would otherwise have been offered. The hospital saved part of the cost through avoided treatment, and the wider economy saved much more by keeping working-age patients at work. The authors stress that smooth testing routines and clinician training made the difference.

Catalog record

CREATORNiina Mäenpää, Leena Tiainen, Janne Martikainen, Minna Tanner, Arja Jukkola, Maarit Bärlund
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE31136
LICENSECC_BY
RIGHTSCC BY
SOURCEPLOS

Source: https://doi.org/10.1371/journal.pone.0353941

Browse the full library · About the Tower of Babel